American College of Allergy, Asthma and Immunology

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

Retrieved on: 
Thursday, November 9, 2023
Anaphylaxis, American College, Session, BMI, Heart rate, Upper respiratory tract infection, ACAAI, Adrenaline, Absorption, Asthma, ARS, Pharmacokinetics, Lower respiratory tract infection, Intramuscular injection, Caregiver, American College of Allergy, Asthma and Immunology, Medicine, Allergy, Patient, Human, Pediatrics, SAN, Pharmaceutical industry

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that clinical data supporting neffy (epinephrine nasal spray) will be presented during the 2023 American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting. The meeting is being held November 9-13, 2023, in Anaheim, California.

Key Points: 
  • Notably, data demonstrate that the pharmacokinetics of neffy are independent of BMI or body weight.
  • Unlike injection products where exposures decreased with varying BMI or body weight, neffy could be a potentially effective epinephrine product in these patients.
  • “Severe allergic reactions can be life-threatening, and today’s standard of care is needle-bearing injectable devices associated with numerous administration challenges.
  • neffy 2.0 mg is expected to be a safe and effective option for the treatment of type I allergic reactions (including anaphylaxis) in patients experiencing upper respiratory tract infections.

Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy

Retrieved on: 
Thursday, November 9, 2023
Anaphylaxis, Oral food challenge, American College, OMEGA, Clinical trial, ACAAI, MD, Food, Asthma, American College of Allergy, Asthma and Immunology, Safety, Therapy, Patient, Chronic pain, Peanut allergy, Nursing, Pharmaceutical industry

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, will present top-line results of the Phase 1 OMEGA (Oral Mucosal Escalation Goal Assessment) clinical trial during a late-breaking oral presentation at this year’s American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California. The data demonstrates that INT301, an innovative specially formulated toothpaste, can safely be used to deliver Oral Mucosal Immunotherapy (OMIT). The presentation is scheduled for Saturday, November 11 from 9:50 - 10:00 A.M. PST.

Key Points: 
  • The data demonstrates that INT301, an innovative specially formulated toothpaste, can safely be used to deliver Oral Mucosal Immunotherapy (OMIT).
  • The Phase 1 OMEGA Clinical Trial was a 48-week, double-blind, placebo-controlled trial involving 32 adult patients with peanut allergy to assess the safety of INT301.
  • INT301 represents a new approach to peanut desensitization in a fully functioning toothpaste that can easily be incorporated into a patient’s daily toothbrushing routine.
  • These results support further investigation of INT301 for the treatment of peanut allergy.

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

Retrieved on: 
Thursday, November 9, 2023
American College, American College of Allergy, Asthma and Immunology, EOP, Physician, ACAAI, EST, Hereditary angioedema, Poster, DSP, HAE, PST, Adelphi, Angioedema, Attack, Pharmaceutical industry

In the phase 2 RAPIDe-1 trial, PHVS416 (immediate-release deucrictibant capsules) reduced time to the onset of symptom relief and to the resolution of HAE attacks, and substantially reduced use of rescue medication.

Key Points: 
  • In the phase 2 RAPIDe-1 trial, PHVS416 (immediate-release deucrictibant capsules) reduced time to the onset of symptom relief and to the resolution of HAE attacks, and substantially reduced use of rescue medication.
  • “The real-world HAE data and post-hoc analysis of RAPIDe-1 data that will be presented at ACAAI support the compelling story for the ongoing development of PHVS416 for the on-demand treatment of HAE,” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris.
  • An oral therapy with a faster onset of action may encourage more consistent and timely treatment of HAE attacks and improved treatment satisfaction.
  • Results of the post-hoc RAPIDe-1 analysis provide additional evidence on the rapid onset of effects of PHVS416 for on-demand treatment of HAE attacks.”

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
FDA, Research and development, Trial of the century, IND, American College, Association of International Accountants, Food, 2023 International Conference on Climate Resilient Pakistan, ACAAI, Conference, Asthma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hereditary angioedema, R, Bank statement, HAE, American College of Allergy, Asthma and Immunology, ACIS, Abstract, Record, Safety, Attack, Patient, International Accounting Standards Board, Communication, Book, Administration, CIIC, Pharmaceutical industry, Cryptocurrency, Allergy

Results of nonclinical toxicology study on-track to be submitted to the FDA by the end of 2023.

Key Points: 
  • Results of nonclinical toxicology study on-track to be submitted to the FDA by the end of 2023.
  • R&D expenses were €18.5 million for the quarter ended September 30, 2023, compared to €14.1 million for the quarter ended September 30, 2022.
  • G&A expenses were €7.7 million for the quarter ended September 30, 2023, compared to €8.3 million for the quarter ended September 30, 2022.
  • Details are as follows:
    Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

Retrieved on: 
Monday, October 30, 2023
HAE, ACAAI, Abstract, EST, American College, PST, Anaheim Convention Center, Hereditary angioedema, American College of Allergy, Asthma and Immunology, Pharmaceutical industry, Mobile phone

ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2023 Annual Scientific Meeting, to be held from November 9-13, 2023, at the Anaheim Convention Center in Anaheim, CA.

Key Points: 
  • ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2023 Annual Scientific Meeting, to be held from November 9-13, 2023, at the Anaheim Convention Center in Anaheim, CA.
  • On November 9 at 8:30 a.m. PST (11:30 a.m. EST), the ePosters and accompanying audio voice-overs will be made available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, ACAAI, University, Allergy, American College, PST, American College of Allergy, Asthma and Immunology, Therapy, Asthma, Internal medicine, Hereditary angioedema, Pharmaceutical industry, Immunology

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST.

Key Points: 
  • Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST.
  • Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present additional data from the Phase 1a clinical trial of STAR-0215 in a poster titled, “Support for STAR-0215 Administered Every Three- or Six-Months for Hereditary Angioedema: Phase 1a Results” at 12:35pm PST in the ePoster Section – Exhibit Hall, Monitor 12, presentation number P066.

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023
ACAAI, PD, Allergy, Emergency, Investment, ARS, New Drug Application, European Medicines Agency, Clinical trial, NDA, Pharmacokinetics, American Academy, G&A, American Academy of Allergy, Asthma, and Immunology, Marketing, EMA, Pain, Asthma, Patient, Nature, Adrenaline, Rhinitis, SAN, OTC, PDUFA, AAAAI, R, MAA, Research, Caregiver, FDA, American College, Regulation of tobacco by the U.S. Food and Drug Administration, Treatment, Food, American College of Allergy, Asthma and Immunology, D, Vaccine, Pharmaceutical industry, Anaphylaxis

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today highlighted recent progress and reported fourth quarter and full year 2022 financial results.

Key Points: 
  • We believe we are well on our way to achieving this goal,” said Richard Lowenthal, president and chief executive officer of ARS Pharmaceuticals.
  • R&D Expenses: Research and development (R&D) expenses were $4.7 million for the quarter ended December 31, 2022, and $18.4 million for the year ended December 31, 2022.
  • G&A Expenses: General and administrative (G&A) expenses were $10.7 million for the quarter ended December 31, 2022, and $18.5 million for the year ended December 31, 2022.
  • Net Loss: Net loss was $14.4 million for the quarter ended December 31, 2022, and $34.7 million for the year ended December 31, 2022.

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

Retrieved on: 
Tuesday, March 7, 2023
Sale, Growth, Food, Patent, American College of Allergy, Asthma and Immunology, Adrenaline, American Academy of Allergy, Asthma, and Immunology, United States Food Administration, FDA, NDA, Therapy, ATM, Trial of the century, PK, American Academy, Depreciation, AAAAI, Research, Asthma, Anaphylaxis, Tax, ACAAI, American College, EBITDA, Allergy, Plasma, Patient, Emergency, Community, Agreement, Absorption, Epilepsy, Cryptocurrency, Pharmaceutical industry, Video game, Bookkeeping, Clobazam

“Our 2022 results and early progress in 2023 continue to drive the Company towards important upcoming inflection points,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “Our 2022 results and early progress in 2023 continue to drive the Company towards important upcoming inflection points,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • Aquestive anticipates providing a revised pivotal study protocol to the FDA in the second quarter 2023 and starting the pivotal study in the third quarter 2023.
  • Total revenues were $10.7 million in the fourth quarter 2022, compared to $11.1 million in the fourth quarter 2021, a decrease of 4%.
  • During the fourth quarter 2022, the Company accessed capital net proceeds of $0.9 million under its “At-the-Market” (ATM) facility.

Allergist/Immunologist Misu Paul, MD to Join ENT and Allergy Associates, LLP In Bay Ridge and Dyker Heights Brooklyn, NY

Retrieved on: 
Wednesday, January 11, 2023
Otorhinolaryngology, Allergy, Teaching hospital, Internal medicine, Hindi, Asthma, American College of Allergy, Asthma and Immunology, Immunotherapy, American Board of Commissioners for Foreign Missions, Throat, American College, Ear, American Academy of Allergy, Asthma, and Immunology, Knowledge, Hives, Norwegian Asthma and Allergy Association, LLP, Patient, Baylor College of Medicine, American Academy, Atopic dermatitis, Allergist, Research, Audiology, Drug allergy, American Board of Internal Medicine, Dermatitis, Food allergy, Nose, Baylor University, The Stony Brook School, Immunology, Medical device, Adult, MD, Medicine

Dr. Paul is board certified by the American Board of Internal Medicine and the American Board of Allergy and Immunology.

Key Points: 
  • Dr. Paul is board certified by the American Board of Internal Medicine and the American Board of Allergy and Immunology.
  • Dr. Paul is active in the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology.
  • In Bay Ridge, Dr. Paul will work side-by-side with otolaryngologists Ramez Habib, MD, Christopher Song, MD, and Wesley Davidson, MD.
  • In Dyker Heights, she will join otolaryngologists Leon Chen, MD and Wayne Chung, MD.

UNC Health Provider Ushers in First FDA-Approved Medication for Eosinophilic Esophagitis

Retrieved on: 
Thursday, December 22, 2022
Research, General Health, Pharmaceutical, Other Education, Continuing, University, Education, Clinical Trials, Science, FDA, Other Science, Health, The New England Journal of Medicine, Eosinophilic esophagitis, Esophagus, Immunology, Clinical trial, Plasma protein binding, A. Lee Dellon, Communication, Stomach, American College, UNC School of Medicine, Polyp (medicine), Dysphagia, Skin, Dupilumab, Enzyme inhibitor, Inflammation, Multimedia, Food, American College of Allergy, Asthma and Immunology, Irritation, Eosinophil, Patient, Asthma, Infection, Physician, Parasitism, Swelling, FDA, EOE, Regeneron Pharmaceuticals, Sinusitis, Degenerative disease, Colon, Endoscopy, Diagnosis, MPH, Dermatitis, Annals of Allergy, Asthma & Immunology, Biopsy, Electric battery, Pharmaceutical industry, Medical imaging, MD, Allergy, Medicine

Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States.

Key Points: 
  • Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States.
  • View the full release here: https://www.businesswire.com/news/home/20221222005534/en/
    Evan Dellon, MD, MPH, professor of medicine at the UNC School of Medicine and director of the Center for Esophageal Diseases and Swallowing.
  • There is one approved treatment for EoE in several other countries, but it is not available for use in the United States.
  • Dellon believes that initially most doctors will prescribe the therapy for their more severe patients who weren’t responding to prior therapies.